Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Experimental, tissue study. Patients with EGFR receptor amplification/overexpression or activating mutations treated with anti-EGFR cancer therapies will be involved in the study as required in normal clinical practice. Clinical information of the patients, relevant to the conduct of the study, will be collected: age, sex, ethnicity, smoking habit, diagnosis, staging of the tumor, site of any metastases, possible presence of ascites and/or pleural effusion, type of oncological therapy administered, concomitant therapies, radiological re-evaluation of the tumor, response to treatment, survival.
Similarly, peripheral blood, tissue obtained from archival tumor biopsies, ascitic and/or pleural fluid samples (taken, if present, as per clinical practice) will be collected. Primary cell cultures will be derived from tumor biopsies, ascites, and/or pleural effusion for in vitro studies The lymphocyte population will be isolated from the peripheral blood of patients
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
patients aged ≥ 18 years
patients with advanced cancer characterized by amplification/overexpression or activating mutations of the EGFR receptor.
patients who are candidates for treatment with TKI and/or mAbs both in the first and second line, according to clinical practice.
possibility of obtaining all information relating to the clinical history - obtaining written informed consent
You may not be if
Patients who in the opinion of the investigator may not be compliant with the needs of the study
patients suffering from pathologies (e.g. psychiatric, neurological) that do not allow the obtaining of valid informed consent